

    BOXED WARNING: WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST

  WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST

      Infusion Reactions    :   Serious infusion reactions occurred with the administration of Erbitux in approximately 3% of patients in clinical trials, with fatal outcome reported in less than 1 in 1000. [See     Warnings and Precautions (5.1)  ,   Adverse Reactions (6)    .] Immediately interrupt and permanently discontinue Erbitux infusion for serious infusion reactions. [See     Dosage and Administration (2.4)  ,   Warnings and Precautions (5.1)    .]  

     Cardiopulmonary Arrest    :   Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with Erbitux and radiation therapy in Study 1 and in 3% of patients with squamous cell carcinoma of the head and neck treated with European Union (EU)-approved cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU) in Study 2. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration. [See     Warnings and Precautions (5.2  ,   5.6)  ,   Clinical Studies (14.1)    .]  

   EXCERPT:   WARNING: SERIOUS INFUSION REACTIONSand CARDIOPULMONARY ARREST  See full prescribing information for complete boxed warning.  

 *  Serious infusion reactions, some fatal, occurred in approximately 3% of patients. (5.1) 
 *  Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with Erbitux and radiation therapy and in 3% of patients with squamous cell carcinoma of the head and neck treated with cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU). Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration. (5.2, 5.6) 
    

